E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 8/4/2006 in the Prospect News Biotech Daily.

Pozen rated at outperform by RBC

RBC Capital Markets analyst Ken Trbovich rated Pozen, Inc. at outperform, speculative risk. The company reported revenue of $887,000, missing RBC's $2.2 million estimate due to the extended amortization period of the upfront Trexima payment until the second-quarter 2007. Pozen raised its 2006 guidance to $12 million to $14 million in recurring revenue from $6 million to $10 million. Shares of the Chapel Hill, N.C.-based development-stage company were down 14 cents, or 1.34%, at $10.31 on volume of 1,355,795 shares versus the three-month running average of 1,690,940 shares. (Nasdaq: POZN)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.